It is also conceivable that HSP90/AXL/eIF4E signaling strength, ER stress magnitudes, and UPR status may stratify subsets of patients with KRAS-mutant lung cancer who likely benefit from the combination therapy. This evidence concerns the gene KRAS and lung carcinoma.